HK Stock Market Move | INNOCARE (09969) surged more than 6% in early trading. The BCL2 inhibitor Mesutoclax for the treatment of AML and MDS has been approved for clinical use in the United States.

INNOCARE (09969)rose more than 6% in early trading, and as of the time of this report, it had risen by 5.24% to HK$17.26, with a trading volume of HK$194 million. On the news front, INNOCARE announced that its independently developed novel BCL2 inhibitor mesutoclax (ICP-248) in combination with azacitidine for the treatment of myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), has received approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials. Public information shows that Mesutoclax is a new orally selective BCL2 inhibitor, with BCL2 being an important regulatory protein in the cellular apoptosis pathway, and its abnormal expression is related to the occurrence and development of various malignant hematologic tumors. Mesutoclax selectively inhibits BCL2, restoring the programmed cell death mechanism in tumor cells, thereby exerting anti-tumor effects.